Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Low systemic exposure in infants with atopic dermatitis in a 1‐year pharmacokinetic study with pimecrolimus cream 1% *

Low systemic exposure in infants with atopic dermatitis in a 1‐year pharmacokinetic study with... Abstract: Systemic drug exposure following the application of topical agents is a very important safety consideration, particularly in infants, who have a significantly higher ratio of body surface area to body mass than older children and adults. Here, we report on drug exposure in five infants aged 5.7–11.9 months at baseline, with extensive, moderate‐to‐severe atopic dermatitis (AD). Patients were treated bid for 1 year, as needed, with pimecrolimus cream 1% in an open‐label, non‐controlled study. No indication of drug accumulation was found; pimecrolimus blood concentrations were consistently low, ranging from below the limit of quantitation (0.1 ng/ml) to 1.94 ng/ml. Treatment over this prolonged period was well tolerated, with no evidence of any treatment‐related adverse events. The results of this 1‐year study indicate that long‐term management of AD with pimecrolimus cream 1% is associated with consistently very low systemic absorption, even in the youngest patients with extensive disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Experimental Dermatology Wiley

Low systemic exposure in infants with atopic dermatitis in a 1‐year pharmacokinetic study with pimecrolimus cream 1% *

Loading next page...
 
/lp/wiley/low-systemic-exposure-in-infants-with-atopic-dermatitis-in-a-1-year-BkebimQqPB

References (13)

Publisher
Wiley
Copyright
Copyright © 2006 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0906-6705
eISSN
1600-0625
DOI
10.1111/j.1600-0625.2006.00398.x
pmid
16433686
Publisher site
See Article on Publisher Site

Abstract

Abstract: Systemic drug exposure following the application of topical agents is a very important safety consideration, particularly in infants, who have a significantly higher ratio of body surface area to body mass than older children and adults. Here, we report on drug exposure in five infants aged 5.7–11.9 months at baseline, with extensive, moderate‐to‐severe atopic dermatitis (AD). Patients were treated bid for 1 year, as needed, with pimecrolimus cream 1% in an open‐label, non‐controlled study. No indication of drug accumulation was found; pimecrolimus blood concentrations were consistently low, ranging from below the limit of quantitation (0.1 ng/ml) to 1.94 ng/ml. Treatment over this prolonged period was well tolerated, with no evidence of any treatment‐related adverse events. The results of this 1‐year study indicate that long‐term management of AD with pimecrolimus cream 1% is associated with consistently very low systemic absorption, even in the youngest patients with extensive disease.

Journal

Experimental DermatologyWiley

Published: Feb 1, 2006

There are no references for this article.